Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 83-89

  Wen, M S ^a   Lee, M T M ^b,c   Chen, J J ^b,d   Chuang, H P ^b   Lu, L S ^b   Chen, C H ^b,c   Lee, T H ^a   Kuo, C T ^a   Sun, F M ^b   Chang, Y J ^a   Kuan, P L ^e   Chen, Y F ^f   Charng, M J ^g   Ray, C Y ^a,h   Wu, J Y ^a,b   Chen, Y T ^b,i  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; HERBACEOUS AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ROSUVASTATIN; VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; CHINESE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; FEMALE; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; WARFARIN;

EID: 42549147841     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100453     Document Type: Article

References (38)

1. Hirsh, J. Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. Am. Heart J. 123, 1115-1122 (1992).
2. Hirsh, J. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 (suppl. 1), 8S-21S (2001).
3. Laupacis, A. et al. Antithrombotic therapy in atrial fibrillation. Chest 108, 352S-359S (1995).
4. Stein, P.D. et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 108, 371S-379S (1995).
5. Loebstein, R. et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70, 159-164 (2001).
6. Takahashi, H. et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263 (2003).
7. Zhao, F. et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76, 210-219 (2004).
8. Bogousslavsky, J. & Regli, F. Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke. Acta Neurol. Scand. 71, 464-471 (1985).
9. Gullov, A.L., Koefoed, B.G. & Petersen, P. Bleeding complications to long-term oral anticoagulant therapy. J. Thromb. Thrombolysis 1, 17-25 (1994).
10. Landefeld, C.S. & Beyth, R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95, 315-328 (1993).
11. Miners, J.O. & Birkett, D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538 (1998).
12. Rettie, A.E. et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
13. Takahashi, H. & Echizen, H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40, 587-603 (2001).
14. Furuya, H. et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392 (1995).
15. Nasu, K., Kubota, T. & Ishizaki, T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409 (1997).
16. Xie, H.G., Prasad, H.C., Kim, R.B. & Stein, C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002).
17. Bell, R.G. & Matschiner, J.T. Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature 237, 32-33 (1972).
18. Wallin, R. & Martin, L.F. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J. Clin. Invest. 76, 1879-1884 (1985).
19. Yuan, H.Y. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
20. Bodin, L. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
21. Obayashi, K. et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178 (2006).
22. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
23. Hillman, M.A. et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3, 137-145 (2005).
24. Voora, D. et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93, 700-705 (2005).
25. D'Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
26. Sconce, E.A. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
27. Takahashi, H. et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
28. Millican, E. et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110, 1511-1515 (2007).
29. Yin, T. & Miyata, T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb. Res. 120, 1-10 (2007).
30. Higashi, M.K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
31. Beyth, R.J., Quinn, L. & Landefeld, C.S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann. Intern. Med. 133, 687-95 (2000).
32. Levine, M.N., Raskob, G., Landefeld, S. & Hirsh, J. Hemorrhagic complications of anticoagulant treatment. Chest 108, 276S-290S (1995).
33. Herman, D., Peternel, P., Stegnar, M., Breskvar, K. & Dolzan, V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95, 782-787 (2006).
34. Sconce, E.A., Daly, A.K., Khan, T.I., Wynne, H.A. & Kamali, F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet. Genomics 16, 609-611 (2006).
35. Vecsler, M. et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost. 95, 205-211 (2006).
36. Wadelius, M. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
37. Wadelius, M. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
38. Sullivan-Klose, T.H. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).